Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer

Akinori Sasaki(Osaka University of Pharmaceutical Sciences), Kohei Shitara(National Cancer Center Hospital East)

Gastric Cancer

January 9, 2019

10.1007/s10120-018-00922-8

Cited by 158

Related Papers

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2018|1.3k

Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments

|Cancer Cell|2022|828

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

|Nature Immunology|2020|810

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

|The Lancet|2023|701

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

|Nature|2021|687